Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
2 Months : From Sep 2019 to Nov 2019
By Michael Dabaie
Abbott Laboratories (ABT) said its Architect Stat High Sensitivity Troponin-I blood test received clearance from the U.S. Food and Drug Administration.
The technology helps detect heart attacks faster and more accurately than contemporary troponin tests, the company said.
Abbott's blood test, known as High Sensitive Troponin-I in Europe and Asia, has been used throughout hospitals internationally and researched in more than 200 studies for its role in identifying heart disease and cardiac events, Abbott said.
With this clearance, the blood test may be sold in the U.S. for use on Abbott's fully automated Architect analyzer.
Write to Michael Dabaie at email@example.com
(END) Dow Jones Newswires
September 25, 2019 08:37 ET (12:37 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.